Asoglu H, Lampmann T, Jaber M, Khalafov L, Dittmer J, Ilic I, Gielen G H, Toma M, Vatter H, Bendella Z, Schneider M, Schmeel C, Hamed M, Banat M
Department of Neurosurgery, University Hospital Bonn, Bonn / Venusberg-Campus 1, 53127, Bonn, Germany.
Department of Neuropathology, University Hospital Bonn, Bonn, Germany.
J Cancer Res Clin Oncol. 2025 Mar 10;151(3):105. doi: 10.1007/s00432-025-06142-9.
Bone mineral density (BMD) plays a crucial role in diagnosing and treating various systemic chronic diseases. Patients with multiple or singular spinal metastasis (SM) are typically in advanced stages of systemic cancer, often leading to significant alterations in BMD. The present study investigated the prognostic value of perioperative Hounsfield units (HU) as a surrogate independent marker for estimated BMD in patients with SM after surgical treatment (ST).
HU values, serving as a surrogate for estimated BMD, were measured from circular regions of interest (ROIs) in the spine -first lumbar vertebra (L1)- from routine preoperative staging computed tomography (CT) scans in 187 patients after ST. The estimated BMD was stratified into pathologic and physiologic values and correlated with survival parameters in our cohorts.
Median L1 BMD of 92 patients (49%) with pathologic BMD was 79.5 HU (IQR 67.25-93.5) compared to 145 HU (IQR 123-166) for 95 patients (51%) with physiologic BMD (p ≤ 0.001). Patients with pathological BMD exhibited a median overall survival of 8 months compared to 12.2 months in patients with physiologic BMD (p = 0.006). Multivariable analysis revealed pathologic BMD as an independent negative prognostic predictor for increased 1 year mortality (AUC: 0.637, 95% CI: 0.556-0.718; p = 0.001).
The present study demonstrates that decreased perioperative BMD values, as derived from HU measurements, may represent a previously unrecognized negative prognostic factor in patients of SM after ST. The estimated perioperative BMD could emerge as an individualized, readily available potential biomarker for prognostic, treatment, and discussion of affected patients with SM.
骨密度(BMD)在各种全身性慢性疾病的诊断和治疗中起着至关重要的作用。患有多发性或单发性脊柱转移(SM)的患者通常处于全身性癌症的晚期,常常导致骨密度发生显著改变。本研究调查了围手术期亨氏单位(HU)作为手术治疗(ST)后SM患者估计骨密度的替代独立标志物的预后价值。
在187例ST后的患者中,从常规术前分期计算机断层扫描(CT)图像上第一腰椎(L1)的脊柱圆形感兴趣区域(ROI)测量HU值,将其作为估计骨密度的替代指标。将估计的骨密度分为病理值和生理值,并与我们队列中的生存参数相关联。
92例(49%)骨密度为病理值的患者L1骨密度中位数为79.5 HU(四分位间距67.25 - 93.5),而95例(51%)骨密度为生理值的患者为�145 HU(四分位间距123 - 166)(p≤0.001)。骨密度为病理值的患者总生存期中位数为8个月,而骨密度为生理值的患者为12.2个月(p = 0.006)。多变量分析显示,病理骨密度是1年死亡率增加的独立负性预后预测因素(曲线下面积:0.637,95%置信区间:0.556 - 0.718;p = 0.001)。
本研究表明,通过HU测量得出的围手术期骨密度值降低可能是ST后SM患者一个先前未被认识的负性预后因素。估计的围手术期骨密度可能成为一种个体化、易于获得的潜在生物标志物,用于受影响的SM患者的预后评估、治疗及讨论。